Heather Hampel, MS, City of Hope, Duarte, CA, provides an overview for limitations to providing universal germline testing in patients with colorectal cancer (CRC). Higher numbers of patients, who are diagnosed and survive CRC compared to patients with cancers that provide testing for everyone, limit the availability of testing for all patients with CRC. The limited number of genetic counsellors, and the need to retroactively test patients who have undergone treatment will additionally hamper efforts. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.